Eriocitrin Improves Adiposity and Related Metabolic Disorders in High-Fat Diet-Induced Obese Mice.

@article{Kwon2020EriocitrinIA,
  title={Eriocitrin Improves Adiposity and Related Metabolic Disorders in High-Fat Diet-Induced Obese Mice.},
  author={Eun-young Kwon and Myung-Sook Choi},
  journal={Journal of medicinal food},
  year={2020},
  volume={23 3},
  pages={
          233-241
        }
}
Eriocitrin (EC) is an abundant flavonoid in lemons, which is known as a strong antioxidant agent. This study investigated the biological and molecular mechanisms underlying the anti-obesity effect of EC in high-fat diet (HFD)-fed obese mice. C57BL/6N mice were fed an HFD (40 kcal% fat) with or without 0.005% (w/w) EC for 16 weeks. Dietary EC improved adiposity by increasing adipocyte fatty acid (FA) oxidation, energy expenditure, and mRNA expression of thermogenesis-related genes in brown… Expand
Citrus limon Peel Powder Reduces Intestinal Barrier Defects and Inflammation in a Colitic Murine Experimental Model
TLDR
LP powder reduced intestinal damage through the protection of tight junction barriers and suppressed an inflammatory reaction in colitic mice, suggesting that acetate and n-butyrate produced from the microbial metabolism of dietary fibers in LP powder contributed to reducing colitis. Expand
Preliminary Results of CitraVesTM Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study
Appropriate monitoring and control of modifiable risk factors, such as the level of lowdensity lipoprotein cholesterol (LDL-C) and other types of dyslipidemia, have an important role in theExpand
Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study
TLDR
The results support the use of EV extracts to manage cardiometabolic risk factors successfully and evaluate the effects of a natural product containing plant-derived EVs on modifiable risk factors in healthy volunteers for the first time. Expand
Citrus species: Modern functional food and nutraceutical-based product ingredient
  • Mariarosaria Leporini, Rosa Tundis, V. Sicari, M. Loizzo
  • Italian Journal of Food Science
  • 2021
Citrus is the most cultivated fruit crop in the world and occupies a place of considerable importance in the country’s economy. Almost 33% of the citrus fruits are processed for juice production;Expand

References

SHOWING 1-10 OF 29 REFERENCES
Luteolin Attenuates Hepatic Steatosis and Insulin Resistance Through the Interplay Between the Liver and Adipose Tissue in Mice with Diet-Induced Obesity
TLDR
In high fat–fed mice, luteolin improved hepatic steatosis by suppressing hepatic lipogenesis and lipid absorption and improving hepatic insulin sensitivity by suppressing SREBP1 expression that modulates Irs2 expression through its negative feedback and gluconeogenesis. Expand
Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis
TLDR
Dietary eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis and increases mitochondrial size and mtDNA content, which resulted in ATP production in HepG2 cells and zebrafish. Expand
Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity
TLDR
SL, especially its flavonoid glycosides (SLG), can protect against the deleterious effects of diet-induced obesity (DIO) and its metabolic complications such as adiposity, dyslipidemia, inflammation, hepatic steatosis, and insulin resistance. Expand
Lessons from Mouse Models of High-Fat Diet-Induced NAFLD
TLDR
The pathophysiology of and treatment strategies for nonalcoholic fatty liver disease and subsequent NAFLD-related complications such as NASH and liver tumorigenesis are discussed, mainly based on lessons learned from mouse models of high-fat diet-inducedNAFLD/NASH. Expand
Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance.
TLDR
Increased gene expression promoting lipid accumulation and lipolysis in visceral fat, as well as elevated rate-limiting gluconeogenic enzyme expression in the liver, is consistent with the portal theory. Expand
Regulation of UCP1 in the Browning of Epididymal Adipose Tissue by β3-Adrenergic Agonist: A Role for MicroRNAs
TLDR
It is demonstrated that this increase of UCP1 is due, at least in part, to the decreased expression of certain U CP1-targeting miRNAs in epididymal adipose tissue compared to control. Expand
Brown Adipose Tissue Transplantation Reverses Obesity in Ob/Ob Mice.
TLDR
BAT transplantation led to a significant reduction of body weight gain with increased oxygen consumption and decreased total body fat mass, resulting in improvement of insulin resistance and liver steatosis and demonstrate that BAT transplantation may reduce obesity and its related diseases by activating endogenous BAT. Expand
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
TLDR
The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades. Expand
Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications
TLDR
Obese diabetic animals with compromised GIP action due to peptide-based GIP receptor antagonists, small molecular weight GIPceptor antagonists, vaccination against GIP, genetic knockout of GIP receptors or targeted K-cell destruction are protected against obesity and associated metabolic disturbances. Expand
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association
TLDR
Hyperinsulinemia and insulin resistance occur frequently in patients with NASH; these conditions do not stem from a reduced hepatic insulin extraction but from an enhanced pancreatic insulin secretion compensatory to reduced insulin sensitivity. Expand
...
1
2
3
...